Original Research J Clin Psychiatry February 2017

Effectiveness of Supplementary Cognitive-Behavioral Therapy for Pharmacotherapy-Resistant Depression: A Randomized Controlled Trial

JCP 2017;78(8):10.4088/JCP.15m10511

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2017;78(8):10.4088/JCP.15m10511 Clinical Summary Many patients with major depressive disorder remain symptomatic despite an adequate antidepressant trial, and specialty-care clinicians often have no clear next step beyond further medication changes. This trial addresses whether adding cognitive-behavioral therapy to ongoing medication management improves outcomes in pharmacotherapy-resistant depression treated in psychiatric specialty care. FAQ Does adding cognitive-behavioral therapy help patients with pharmacotherapy-resistant major depressive disorder who are already taking antidepressants? 10 questions
Key Takeaways The acute benefit was not evident at 8 weeks (P = .11), but was significant by 16 weeks, which supports setting expectations that adjunctive cognitive-behavioral therapy may require a full course before clear separation from usual medication management emerges. 6 takeaways Clinical Guide How should clinicians identify and treat outpatients with pharmacotherapy-resistant major depressive disorder using adjunctive cognitive-behavioral therapy? 8 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe